Division of Acquired Immunodeficiency Syndrome

NIAID HIV AIDS clinical trials networks.webp

Division of Acquired Immunodeficiency Syndrome (DAIDS)

The Division of Acquired Immunodeficiency Syndrome (DAIDS) is a division within the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH). DAIDS was established to address the growing health crisis posed by the HIV/AIDS epidemic. The division plays a crucial role in the research, development, and implementation of strategies to prevent, diagnose, and treat HIV/AIDS.

History

DAIDS was founded in response to the HIV/AIDS epidemic that emerged in the early 1980s. The division was created to coordinate and support research efforts aimed at understanding the virus, developing effective treatments, and finding a cure. Over the years, DAIDS has been instrumental in advancing the scientific understanding of HIV and AIDS, leading to significant breakthroughs in treatment and prevention.

Mission

The mission of DAIDS is to reduce the global burden of HIV/AIDS through research and development. This includes:

• Supporting basic and clinical research to understand the pathogenesis of HIV.
• Developing and testing new therapies and vaccines.
• Implementing strategies to prevent HIV transmission.
• Enhancing the capacity for HIV/AIDS research in resource-limited settings.

Research Programs

DAIDS supports a wide range of research programs, including:

• Basic research: Investigating the fundamental mechanisms of HIV infection and disease progression.
• Clinical trials: Conducting studies to evaluate the safety and efficacy of new treatments and vaccines.
• Epidemiology: Studying the distribution and determinants of HIV/AIDS in populations.
• Behavioral research: Understanding the social and behavioral factors that influence HIV transmission and treatment adherence.

Key Initiatives

Some of the key initiatives led by DAIDS include:

• The HIV Vaccine Trials Network (HVTN): A global network of clinical trial sites dedicated to developing a safe and effective HIV vaccine.
• The AIDS Clinical Trials Group (ACTG): A network that conducts clinical trials to improve the treatment and management of HIV/AIDS.
• The Microbicide Trials Network (MTN): Focused on developing and testing products that can be applied topically to prevent HIV infection.

Collaborations

DAIDS collaborates with various national and international organizations, including:

• World Health Organization (WHO)
• Centers for Disease Control and Prevention (CDC)
• United Nations Programme on HIV/AIDS (UNAIDS)
• Bill & Melinda Gates Foundation

Impact

The work of DAIDS has led to significant advancements in the fight against HIV/AIDS. The division's efforts have contributed to the development of antiretroviral therapies that have transformed HIV from a fatal disease to a manageable chronic condition. Additionally, DAIDS-supported research has been pivotal in the development of preventive measures such as pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP).

Future Directions

DAIDS continues to focus on innovative research to achieve the ultimate goal of an HIV cure and a vaccine. The division is also committed to addressing the disparities in HIV treatment and prevention, particularly in resource-limited settings.

See Also

• HIV/AIDS
• National Institute of Allergy and Infectious Diseases
• National Institutes of Health
• HIV Vaccine Trials Network
• AIDS Clinical Trials Group
• Microbicide Trials Network